< content="width=device-width, initial-scale=1.0"> PARCKA/GIN Study Endorsed | Internal Medicine | U of U School of Medicine
Skip to main content

PARCKA/GIN Study Endorsed


GIN Study Endorsed

March 29, 2021

The Program for Addiction Research, Clinical Care, Knowledge, and Advocacy (PARCKA) and the Greater Intermountain Node (GIN) are pleased to announce that the Healthy Living Study (HLS) (CTN-0101) has been endorsed to begin enrollment.

CTN-0101 will examine the efficacy of early behavioral intervention to reduce risky opioid use and overdose risk in adult primary care patients, with the goal of preventing opioid use disorder. The intervention is a collaborative care model consisting of brief advice delivered by a primary care provider, a clinic-embedded nurse care manager who provides patient education and care management, and telephone heath coaching sessions promoting and supporting behavior change. This CTN-0101 study is a multisite, national cluster-randomized trial, randomized at the level of the provider, that is being carried out in five sites around the United States. The Utah site will be conducted within two University of Utah Health clinics, including Redwood and Madsen clinics, and aims to enroll 96 patients over the next 12 months.

HLS is currently being led here in Utah by a Site Principal Investigator, Adam J. Gordon, MD MPH; Clinical Champion, Michael Incze, MD; Site Coordinator, Elizabeth (Betsy) Charron, PhD MPH; and our HLS research team.

Learn more about the HLS study and other PARCKA/GIN research here.